18 research outputs found
Advanced age is associated with worsened outcomes and a unique genomic response in severely injured patients with hemorrhagic shock
Abdominal aortic aneurysm is associated with a variant in low-density lipoprotein receptor-related protein 1
Abdominal aortic aneurysm (AAA) is a common cause of morbidity and mortality and has a significant heritability. We carried out a genome-wide association discovery study of 1866 patients with AAA and 5435 controls and replication of promising signals (lead SNP with a p value < 1 Ă 10-5) in 2871 additional cases and 32,687 controls and performed further follow-up in 1491 AAA and 11,060 controls. In the discovery study, nine loci demonstrated association with AAA (p < 1 Ă 10-5). In the replication sample, the lead SNP at one of these loci, rs1466535, located within intron 1 of low-density-lipoprotein receptor-related protein 1 (LRP1) demonstrated significant association (p = 0.0042). We confirmed the association of rs1466535 and AAA in our follow-up study (p = 0.035). In a combined analysis (6228 AAA and 49182 controls), rs1466535 had a consistent effect size and direction in all sample sets (combined p = 4.52 Ă 10-10, odds ratio 1.15 [1.10-1.21]). No associations were seen for either rs1466535 or the 12q13.3 locus in independent association studies of coronary artery disease, blood pressure, diabetes, or hyperlipidaemia, suggesting that this locus is specific to AAA. Gene-expression studies demonstrated a trend toward increased LRP1 expression for the rs1466535 CC genotype in arterial tissues; there was a significant (p = 0.029) 1.19-fold (1.04-1.36) increase in LRP1 expression in CC homozygotes compared to TT homozygotes in aortic adventitia. Functional studies demonstrated that rs1466535 might alter a SREBP-1 binding site and influence enhancer activity at the locus. In conclusion, this study has identified a biologically plausible genetic variant associated specifically with AAA, and we suggest that this variant has a possible functional role in LRP1 expression
Genome-wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the pathophysiology of type 2 diabetes.
OBJECTIVE: Proinsulin is a precursor of mature insulin and C-peptide. Higher circulating proinsulin levels are associated with impaired ÎČ-cell function, raised glucose levels, insulin resistance, and type 2 diabetes (T2D). Studies of the insulin processing pathway could provide new insights about T2D pathophysiology. RESEARCH DESIGN AND METHODS: We have conducted a meta-analysis of genome-wide association tests of âŒ2.5 million genotyped or imputed single nucleotide polymorphisms (SNPs) and fasting proinsulin levels in 10,701 nondiabetic adults of European ancestry, with follow-up of 23 loci in up to 16,378 individuals, using additive genetic models adjusted for age, sex, fasting insulin, and study-specific covariates. RESULTS: Nine SNPs at eight loci were associated with proinsulin levels (P < 5 Ă 10(-8)). Two loci (LARP6 and SGSM2) have not been previously related to metabolic traits, one (MADD) has been associated with fasting glucose, one (PCSK1) has been implicated in obesity, and four (TCF7L2, SLC30A8, VPS13C/C2CD4A/B, and ARAP1, formerly CENTD2) increase T2D risk. The proinsulin-raising allele of ARAP1 was associated with a lower fasting glucose (P = 1.7 Ă 10(-4)), improved ÎČ-cell function (P = 1.1 Ă 10(-5)), and lower risk of T2D (odds ratio 0.88; P = 7.8 Ă 10(-6)). Notably, PCSK1 encodes the protein prohormone convertase 1/3, the first enzyme in the insulin processing pathway. A genotype score composed of the nine proinsulin-raising alleles was not associated with coronary disease in two large case-control datasets. CONCLUSIONS: We have identified nine genetic variants associated with fasting proinsulin. Our findings illuminate the biology underlying glucose homeostasis and T2D development in humans and argue against a direct role of proinsulin in coronary artery disease pathogenesis
Risk Factors for Preoperative Hyperglycemia in Surgical Patients with Diabetes: A CaseâControl Study
Background: Patients with diabetes are more likely to undergo a surgical procedure than the rest of the population, and it is well established that preoperative hyperglycemia is associated with adverse surgical outcomes. However, it is currently unknown what factors increase the odds of preoperative hyperglycemia in people with diabetes.Â
Objective: To identify patient characteristics that increase the risk of preoperative hyperglycemia.Â
Methods: This retrospective caseâcontrol study compared 100 patients with preoperative hyperglycemia on admission for elective surgery at South Health Campus in Calgary, Alberta (blood glucose > 10.9 mmol/L) with 200 controls who did not have preoperative hyperglycemia on admission for elective surgery (blood glucose †10.9 mmol/L). Multivariate logistic regression was used to identify risk factors for preoperative hyperglycemia.Â
Results: In the univariate analysis, age, number of comorbidities, increasing glycated hemoglobin (HbA1c), type of diabetes, type of procedure, and diabetes medications (non-insulin, insulin, both, or none) were associated with increased odds of preoperative hyperglycemia (p < 0.05). However, in the adjusted analysis, only increasing HbA1c (odds ratio [OR] 1.69, 95% confidence interval [CI] 1.36â2.12) and type 1 diabetes (OR 4.24, 95% CI 1.11â16.21, relative to type 2 diabetes) were associated with preoperative hyperglycemia.Â
Conclusions: These results can help clinicians to identify patients who may be at increased risk of hyperglycemia before an elective procedure. They also allow for treatment of those who would benefit most from additional guidance with regard to preoperative glucose management.Â
RĂSUMĂÂ
Contexte : Les patients diabĂ©tiques sont plus susceptibles que le reste de la population de subir une intervention chirurgicale, et il est bien connu que lâhyperglycĂ©mie prĂ©opĂ©ratoire est associĂ©e Ă des rĂ©sultats chirurgicaux indĂ©sirables. Cependant, on ignore actuellement quels facteurs augmentent ce risque chez les personnes atteintes de diabĂšte.Â
Objectif : DĂ©terminer les caractĂ©ristiques des patients qui augmentent le risque dâhyperglycĂ©mie prĂ©opĂ©ratoire.Â
MĂ©thodes : Cette Ă©tude cas-tĂ©moins rĂ©trospective a comparĂ© 100 patients prĂ©sentant une hyperglycĂ©mie prĂ©opĂ©ratoire Ă lâadmission pour une intervention chirurgicale non urgente au South Health Campus de Calgary, en Alberta (glycĂ©mie > 10,9 mmol/L) avec 200 tĂ©moins qui nâen prĂ©sentaient pas (glycĂ©mie †10,9 mmol/L). La dĂ©termination des facteurs de risque dâhyperglycĂ©mie prĂ©opĂ©ratoire sâest faite par rĂ©gression logistique multivariĂ©e.Â
RĂ©sultats : Dans lâanalyse univariĂ©e, lâĂąge, le nombre de comorbiditĂ©s, lâaugmentation du taux dâhĂ©moglobine glyquĂ©e (HbA1c), le type de diabĂšte, le type dâintervention et les mĂ©dicaments contre le diabĂšte (non-insuline, insuline, les deux ou aucun) Ă©taient associĂ©s Ă un risque accru dâhyperglycĂ©mie prĂ©opĂ©ratoire (p < 0,05). Cependant, dans lâanalyse ajustĂ©e, seuls lâaugmentation de lâHbA1c (rapport de cotes [RC] 1,69; intervalle de confiance [IC] Ă 95 % 1,36-2,12) et le diabĂšte de type 1 (RC 4,24; IC Ă 95 % 1,11-16,21, par rapport au diabĂšte de type 2) Ă©taient associĂ©s Ă une hyperglycĂ©mie prĂ©opĂ©ratoire.Â
Conclusions : Ces rĂ©sultats peuvent aider les cliniciens Ă repĂ©rer les patients qui pourraient prĂ©senter un plus grand risque dâhyperglycĂ©mie avant une intervention non urgente. Ils permettent Ă©galement de traiter ceux qui bĂ©nĂ©ficieraient le plus de conseils supplĂ©mentaires en matiĂšre de gestion prĂ©opĂ©ratoire de la glycĂ©mie.
Un blocage neuromusculaire prolongé (plus de dix heures) aprÚs une intervention en cardiochirurgie: présentation de deux cas
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report
: Positive results from recent clinical trials have significantly expanded current therapeutic options for patients with chronic graft-versus-host disease (GVHD). However, new insights into the associations between clinical characteristics of chronic GVHD, pathophysiologic mechanisms of disease, and the clinical and biological effects of novel therapeutic agents are required to allow for a more individualized approach to treatment. The current report is focused on setting research priorities and direction in the treatment of chronic GVHD. Detailed correlative scientific studies should be conducted in the context of clinical trials to evaluate associations between clinical outcomes and the biological effect of systemic therapeutics. For patients who require systemic therapy but not urgent initiation of glucocorticoids, clinical trials for initial systemic treatment of chronic GVHD should investigate novel agents as monotherapy without concurrently starting glucocorticoids, to avoid confounding biological, pathological, and clinical assessments. Clinical trials for treatment-refractory disease should specifically target patients with incomplete or suboptimal responses to most recent therapy who are early in their disease course. Close collaboration between academic medical centers, medical societies, and industry is needed to support an individualized, biology-based strategic approach to chronic GVHD therapy
Opioids for Chronic Noncancer Pain : a Systematic Review and Meta-analysis
Importance: Harms and benefits of opioids for chronic noncancer pain remain unclear. Objective: To systematically review randomized clinical trials (RCTs) of opioids for chronic noncancer pain. Data Sources and Study Selection: The databases of CENTRAL, CINAHL, EMBASE, MEDLINE, AMED, and PsycINFO were searched from inception to April 2018 for RCTs of opioids for chronic noncancer pain vs any nonopioid control. Data Extraction and Synthesis: Paired reviewers independently extracted data. The analyses used random-effects models and the Grading of Recommendations Assessment, Development and Evaluation to rate the quality of the evidence. Main Outcomes and Measures: The primary outcomes were pain intensity (score range, 0-10 cm on a visual analog scale for pain; lower is better and the minimally important difference [MID] is 1 cm), physical functioning (score range, 0-100 points on the 36-item Short Form physical component score [SF-36 PCS]; higher is better and the MID is 5 points), and incidence of vomiting. Results: Ninety-six RCTs including 26169 participants (61% female; median age, 58 years [interquartile range, 51-61 years]) were included. Of the included studies, there were 25 trials of neuropathic pain, 32 trials of nociceptive pain, 33 trials of central sensitization (pain present in the absence of tissue damage), and 6 trials of mixed types of pain. Compared with placebo, opioid use was associated with reduced pain (weighted mean difference [WMD], -0.69 cm [95% CI, -0.82 to -0.56 cm] on a 10-cm visual analog scale for pain; modeled risk difference for achieving the MID, 11.9% [95% CI, 9.7% to 14.1%]), improved physical functioning (WMD, 2.04 points [95% CI, 1.41 to 2.68 points] on the 100-point SF-36 PCS; modeled risk difference for achieving the MID, 8.5% [95% CI, 5.9% to 11.2%]), and increased vomiting (5.9% with opioids vs 2.3% with placebo for trials that excluded patients with adverse events during a run-in period). Low- to moderate-quality evidence suggested similar associations of opioids with improvements in pain and physical functioning compared with nonsteroidal anti-inflammatory drugs (pain: WMD, -0.60 cm [95% CI, -1.54 to 0.34 cm]; physical functioning: WMD, -0.90 points [95% CI, -2.69 to 0.89 points]), tricyclic antidepressants (pain: WMD, -0.13 cm [95% CI, -0.99 to 0.74 cm]; physical functioning: WMD, -5.31 points [95% CI, -13.77 to 3.14 points]), and anticonvulsants (pain: WMD, -0.90 cm [95% CI, -1.65 to -0.14 cm]; physical functioning: WMD, 0.45 points [95% CI, -5.77 to 6.66 points]). Conclusions and Relevance: In this meta-analysis of RCTs of patients with chronic noncancer pain, evidence from high-quality studies showed that opioid use was associated with statistically significant but small improvements in pain and physical functioning, and increased risk of vomiting compared with placebo. Comparisons of opioids with nonopioid alternatives suggested that the benefit for pain and functioning may be similar, although the evidence was from studies of only low to moderate quality